|
1
|
Tsugane S and Inoue M: Insulin resistance
and cancer: Epidemiological evidence. Cancer Sci. 101:1073–1079.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neville SE, Boye KS, Montgomery WS,
Iwamoto K, Okamura M and Hayes RP: Diabetes in Japan: A review of
disease burden and approaches to treatment. Diabetes Metab Res Rev.
25:705–716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katanoda K, Matsuda T, Matsuda A, Shibata
A, Nishino Y, Fujita M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report of the trends in cancer incidence and mortality in
Japan. Jpn J Clin Oncol. 43:492–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vargas AJ and Thompson PA: Diet and
nutrient factors in colorectal cancer risk. Nutr Clin Pract.
27:613–623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang XF and Chen JZ: Obesity, the
PI3K/Akt signal pathway and colon cancer. Obes Rev. 10:610–616.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berster JM and Göke B: Type 2 diabetes
mellitus as risk factor for colorectal cancer. Arch Physiol
Biochem. 114:84–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reimer MK, Holst JJ and Ahrén B: Long-term
inhibition of dipeptidyl peptidase IV improves glucose tolerance
and preserves islet function in mice. Eur J Endocrinol.
146:717–727. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nadkarni P, Chepurny OG and Holz GG:
Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl
Sci. 121:23–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frezza EE, Wachtel MS and
Chiriva-Internati M: The multiple faces of glucagon-like
peptide-1-obesity, appetite, and stress: What is next? A review.
Dig Dis Sci. 52:643–649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takasaki K, Takada H, Nakajima T, Ueno K,
Ushiki J and Higo K: Involvement of the active metabolites in the
inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV.
Eur J Pharmacol. 505:237–241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takasaki K, Nakajima T, Ueno K, Nomoto Y
and Higo K: Effects of combination treatment with dipeptidyl
peptidase IV inhibitor and sulfonylurea on glucose levels in rats.
J Pharmacol Sci. 95:291–293. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dubé PE and Brubaker PL: Frontiers in
glucagon-like peptide-2: Multiple actions, multiple mediators. Am J
Physiol Endocrinol Metab. 293:E460–E465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Drozdowski L and Thomson AB: Intestinal
hormones and growth factors: Effects on the small intestine. World
J Gastroenterol. 15:385–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hartmann B, Thulesen J, Kissow H, Thulesen
S, Orskov C, Ropke C, Poulsen SS and Holst JJ: Dipeptidyl peptidase
IV inhibition enhances the intestinotrophic effect of glucagon-like
peptide-2 in rats and mice. Endocrinology. 141:4013–4020. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boushey RP, Yusta B and Drucker DJ:
Glucagon-like peptide 2 decreases mortality and reduces the
severity of indomethacin-induced murine enteritis. Am J Physiol.
277:E937–E947. 1999.PubMed/NCBI
|
|
17
|
Fujiwara K, Inoue T, Yorifuji N, Iguchi M,
Sakanaka T, Narabayashi K, Kakimoto K, Nouda S, Okada T, Ishida K,
et al: Combined treatment with dipeptidyl peptidase 4 (DPP4)
inhibitor sitagliptin and elemental diets reduced
indomethacin-induced intestinal injury in rats via the increase of
mucosal glucagon-like peptide-2 concentration. J Clin Biochem Nutr.
56:155–162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inoue T, Higashiyama M, Kaji I, Rudenkyy
S, Higuchi K, Guth PH, Engel E, Kaunitz JD and Akiba Y: Dipeptidyl
peptidase IV inhibition prevents the formation and promotes the
healing of indomethacin-induced intestinal ulcers in rats. Dig Dis
Sci. 59:1286–1295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iakoubov R, Lauffer LM, Trivedi S, Kim YI
and Brubaker PL: Carcinogenic effects of exogenous and endogenous
glucagon-like peptide-2 in azoxymethane-treated mice.
Endocrinology. 150:4033–4043. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lim JB and Chung HW: Serum ENA78/CXCL5,
SDF-1/CXCL12, and their combinations as potential biomarkers for
prediction of the presence and distant metastasis of primary
gastric cancer. Cytokine. 73:16–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnson RL and Fleet JC: Animal models of
colorectal cancer. Cancer Metastasis Rev. 32:39–61. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yorifuji N, Inoue T, Iguchi M, Fujiwara K,
Kakimoto K, Nouda S, Okada T, Kawakami K, Abe Y, Takeuchi T and
Higuchi K: The dipeptidyl peptidase-4 inhibitor sitagliptin
suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol
Rep. 35:676–682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakanaka T, Inoue T, Yorifuji N, Iguchi M,
Fujiwara K, Narabayashi K, Kakimoto K, Nouda S, Okada T, Kuramoto
T, et al: The effects of a TGR5 agonist and a dipeptidyl peptidase
IV inhibitor on dextran sulfate sodium-induced colitis in mice. J
Gastroenterol Hepatol. 30:(Suppl 1). S60–S65. 2015. View Article : Google Scholar
|
|
24
|
Chavey C and Fajas L: CXCL5 drives obesity
to diabetes, and further. Aging (Albany NY). 1:674–677. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nunemaker CS, Chung HG, Verrilli GM,
Corbin KL, Upadhye A and Sharma PR: Increased serum CXCL1 and CXCL5
are linked to obesity, hyperglycemia, and impaired islet function.
J Endocrinol. 222:267–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim D, Kim J, Yoon JH, Ghim J, Yea K, Song
P, Park S, Lee A, Hong CP, Jang MS, et al: CXCL12 secreted from
adipose tissue recruits macrophages and induces insulin resistance
in mice. Diabetologia. 57:1456–1465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blogowski W, Serwin K, Budkowska M, Salata
D, Dolegowska B, Lokaj M, Prowans P and Starzynska T: Clinical
analysis of systemic and adipose tissue levels of selected
hormones/adipokines and stromal-derived factor-1. J Biol Regul
Homeost Agents. 26:607–615. 2012.PubMed/NCBI
|
|
28
|
Kitahara CM, Trabert B, Katki HA,
Chaturvedi AK, Kemp TJ, Pinto LA, Moore SC, Purdue MP, Wentzensen
N, Hildesheim A and Shiels MS: Body mass index, physical activity,
and serum markers of inflammation, immunity, and insulin
resistance. Cancer Epidemiol Biomarkers Prev. 23:2840–2849. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yazbeck R, Howarth GS and Abbott CA:
Dipeptidyl peptidase inhibitors, an emerging drug class for
inflammatory disease? Trends Pharmacol Sci. 30:600–607. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Busso N, Wagtmann N, Herling C,
Chobaz-Péclat V, Bischof-Delaloye A, So A and Grouzmann E:
Circulating CD26 is negatively associated with inflammation in
human and experimental arthritis. Am J Pathol. 166:433–442. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakagami H, Pang Z, Shimosato T, Moritani
T, Kurinami H, Koriyama H, Tenma A, Shimamura M and Morishita R:
The dipeptidyl peptidase-4 inhibitor teneligliptin improved
endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp
rat model of metabolic syndrome. Hypertens Res. 37:629–635. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li CL, Zhao LJ, Zhou XL, Wu HX and Zhao
JJ: Review on the effect of glucagon-like peptide-1 receptor
agonists and dipeptidyl peptidase-4 inhibitors for the treatment of
non-alcoholic fatty liver disease. J Huazhong Univ Sci Technolog
Med Sci. 35:333–336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang JH, Inoue T, Higashiyama M, Guth PH,
Engel E, Kaunitz JD and Akiba Y: Umami receptor activation
increases duodenal bicarbonate secretion via glucagon-like
peptide-2 release in rats. J Pharmacol Exp Ther. 339:464–473. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Inoue T, Wang JH, Higashiyama M, Rudenkyy
S, Higuchi K, Guth PH, Engel E, Kaunitz JD and Akiba Y: Dipeptidyl
peptidase IV inhibition potentiates amino acid- and bile
acid-induced bicarbonate secretion in rat duodenum. Am J Physiol
Gastrointest Liver Physiol. 303:G810–G816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baldassano S, Amato A, Cappello F, Rappa F
and Mulè F: Glucagon-like peptide-2 and mouse intestinal adaptation
to a high-fat diet. J Endocrinol. 217:11–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
